Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebelumab plus targeted therapy and chemotherapy for conversion of unresectable colorectal cancer liver metastases (Phase II)
ChiCTR2600117031Phase 2Recruiting
- Sponsor
- Cancer Hospital of Shanxi Province
- Start
- Jan 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adebrelimab in colorectal cancer (CRC) and colorectal cancer liver metastasis (CRLM), sponsored by Cancer Hospital of Shanxi Province. Primary endpoint: overall response rate. Started Jan 2026; status: recruiting.
02
Drugs
adebrelimab
03
Conditions
colorectal cancer (CRC)colorectal cancer liver metastasis (CRLM)
Beyond the preview
Go deeper on ChiCTR2600117031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600117031.